Shanghai Shucan Industrial Co.,Ltd
|Place of Origin:||China|
|Minimum Order Quantity:||10gram|
|Packaging Details:||discreet and safe foil bag or tin|
|Delivery Time:||Within 12hours after payment|
|Payment Terms:||West Union, T/T, Money Gram.,Bitcorn and bank transfer|
|Supply Ability:||5000kilogram per month|
|CAS NO:||71-58-9||Molecular Formula:||C24H34O4|
|Appearance:||White Crystalline Powder||Assay:||97%-103%, USP34|
|Packing:||1kg/aluminum Foil Bag||Usage:||Progesterone Medicines For Irregular Menstruation, Functional Uterine Bleeding, Endometriosis|
Synonyms: Medroxyprogesterone 17-acetate
Assay: 97%-103%, USP34
Packing: foil bag or tin. 25kg/drum.
Delivery: Express courier.
Character: white crystalline powder.
Usage: Progesterone medicines for irregular menstruation, functional uterine bleeding, endometriosis. For the treatment of advanced breast cancer, endometrial cancer and kidney cancer.
Product Name: Medroxyprogesterone 17-acetate
Product Categories: Antitumors for Research and Experimental Use;Biochemistry;Hydroxyketosteroids;Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;Steroid and Hormone;API;PROVERA;Hormone Drugs
Mol File: 71-58-9.mol
Medroxyprogesterone acetate (MPA), also known as 17α-hydroxy-6α-methylprogesterone acetate, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications.
In females, the most common use of MPA is as an oral or depot-injected contraceptive and also as the progestin component of menopausal hormone replacement therapy to prevent endometrial hyperplasia and cancer.
MPA is also used as a treatment for endometriosis, dysmenorrhea, and amenorrhea.MPA along with other progestins were developed to allow the hormones to be taken orally, as progesterone (the hormone made by the human body) could not be taken orally before the process of micronization was developed.
MPA is an extremely effective contraceptive when used with relatively high doses to prevent ovulation. It has also been used to treat benign prostatichyperplasia, as a palliative appetite stimulant for cancer patients, and at high doses (800 mg per day) to treat hormone-dependent cancers of primarily the breast,
but also other types.
Though not used as a treatment for epilepsy, MPA reduces the frequency of seizures and does not interact with anti-epileptic medications. MPA does not interfere with blood clotting and appears to improve blood parameters for women with sickle cell anemia. Similarly, MPA does not appear to affect liver metabolism,and may improve primary biliary cirrhosis and chronic active hepatitis. Women taking MPA may experience spotting shortly after starting the medication but is not usually serious enough to require medical intervention. With longer use amenorrhoea can occur as can irregular menstruation which is a major source of dissatisfaction, though both can result in improvements with iron deficiency and risk of pelvic inflammatory disease and often do not result in discontinuing the medication.MPA is also prescribed in combination with an estrogen to prevent endometrial hyperplasia in post-menopausal women who are undergoing hormone replacement therapy.
|Exemestane Acatate||CAS: 107868-30-4|
|Nandrolone phenypropionate /Durabolin|
Boldenone undecylenate (Equipoise)
|Trenbolone Hexahydrobenzyl Carbonate||CAS: 23454-33-3|
Methenolone Enanthate (Primobolan)
|Tamoxifen Citrate /Nolvadex||CAS: 54965-24-1|
|Shanghai Shucan Industrial Co.,LTD.|
|lareina (Sales Manger)|
|No.19 Building,28 Lane Beiyu Road,Changning District,Shanghai, China|
Transportation you may like: